Section Arrow
Quote
ITRM.NASDAQ
- Iterum Therapeutics plc
Quotes are at least 15-min delayed:2025/07/21 06:41 EDT
Pre Market
Last
 0.9349
+0.0183 (+2.00%)
Bid
0.932
Ask
0.9349
High 0.9349 
Low 0.9166 
Volume 727 
Regular Hours
Last
 0.9166
-0.0634 (-6.47%)
Day High 
0.9775 
Prev. Close
0.98 
1-M High
1.28 
Volume 
1.83M 
Bid
0.932
Ask
0.9349
Day Low
0.88 
Open
0.9088 
1-M Low
0.912 
Market Cap 
39.20M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1 
20-SMA 1 
50-SMA 0.98 
52-W High 3.02 
52-W Low 0.808 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.94/-0.05
Enterprise Value
70.27M
Balance Sheet
Book Value Per Share
-0.06
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2 -0.28 -12.28%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.15 -0.925 -6.57%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.21 +0.37 +6.34%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.06 +0.14 +2.36%
Quotes are at least 15-min delayed：2025/07/21 06:41 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.